DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Witzig TE, Gordon LI, Cabanillas F. et al.
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.
J Clin Oncol 2002; 20: 2453-2463
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.